神州细胞(688520) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was CNY 156,015.30 million, a decrease of 37.91% compared to the previous year[3] - Net profit attributable to shareholders of the parent company was CNY -55,329.37 million, a significant decline from CNY 11,195.11 million in the previous year[3] - The equity attributable to shareholders of the parent company decreased by 0.95% to CNY 13,956.18 million[3] Assets and Investments - The company's total assets increased by 16.73% to CNY 383,328.43 million at the end of the reporting period[3] - R&D investments remained high as multiple projects are in late-stage clinical research, contributing to the shift from profit to loss in 2025[6] Revenue Decline Factors - The decline in revenue was primarily due to the deepening of medical insurance cost control policies and multiple price reductions of the core product Anjain®[6] - Sales expenses increased as the company intensified commercialization efforts for newly approved products[6] Non-Operating Income - Non-operating income showed significant fluctuations due to reduced donations and increased government subsidies[7] Cautionary Notes - The company warns that the financial data presented is preliminary and unaudited, with potential discrepancies in the final annual report[8] - Investors are advised to be cautious regarding investment risks associated with the reported financial data[8]